搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
2 小时
Does ‘nature’s Ozempic’ really work? Trendy GLP-1 supplements are designed to ...
Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...
Opinion
3 小时
Opinion
Zeitgeist: ‘Ozempic-like’ supplement is Kourtney Kardashian’s latest way to fatten ...
Kourtney Kardashian knows the world is going through a bit of an Ozempic craze and many people wish there was an easy, ...
3 小时
三位GLP-1研究先驱获2024年拉斯克奖,他们彻底改变了肥胖治疗
拉斯克奖颁奖语提到,全球有近9亿成年人患有肥胖症。体重过重是多种危及生命的疾病的根源。肥胖通常被视为意志力的失败,但对许多人来说,节食和锻炼并不能治愈肥胖问题。从历史上看,制造安全有效的减肥药物的尝试都失败了。哈本纳、莫伊索夫和克努森开创了体重管理的 ...
6 小时
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
6 小时
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
7 小时
While brand-name weight loss drugs are in short supply, a market for alternatives thrives
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...
8 小时
10 Best Hair Care Stocks To Buy Now
According to Fortune Business Insights, in 2023, the hair care industry was estimated to be worth $99.52 billion globally.
STAT
9 小时
First Opinion readers on clinical trials in Africa, compounded semaglutide, depressed mice ...
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...
9 小时
The 5 celebs who have taken ‘skinny jabs’ and their terrifying side effects after ...
WITH all the buzz around the so-called ‘miracle’ weight-loss jabs Ozempic, you could easily mistake it for a cure for all.
11 小时
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...
12 小时
Weight loss surgery cuts kidney failure risk by 44% in diabetics: Study
The study published in the Annals of Surgery found that bariatric surgery was linked to a 60% lower risk of kidney disease ...
12 小时
诺和诺德(NVO.US)GIP/GLP-1双受体激动剂在中国申报临床
根据诺和诺德官网管线资料,该公司拟开发这款GIP/GLP-1受体激动剂用于2型糖尿病和减重。根据ClinicalTrials官网,诺和诺德此前已经在美国、日本、澳大利亚、韩国等地已经启动了NNC0519-0130注射液的多项1期和2期临床研究,计划评 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈